The differences in BoNT\A dosing between MHDA\AB\positive and MHDA\AB\unfavorable patients were not significant for the other treatment groups, again probably because of the low numbers of MHDA\AB\positive patients in these groups, which again is supported by the power analysis

The differences in BoNT\A dosing between MHDA\AB\positive and MHDA\AB\unfavorable patients were not significant for the other treatment groups, again probably because of the low numbers…

Thus C apart from triplicating the number of documented individuals treated with alemtuzumabC the evidence of benefits and risks of alemtuzumab for patients as well as for physicians will appear in much higher resolution and depth when the study ends

Thus C apart from triplicating the number of documented individuals treated with alemtuzumabC the evidence of benefits and risks of alemtuzumab for patients as well…